Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Takeda Pharmaceutical (TKPHF) Interest & Investment Income (2017 - 2025)

Historic Interest & Investment Income for Takeda Pharmaceutical (TKPHF) over the last 9 years, with Q4 2025 value amounting to $570.9 million.

  • Takeda Pharmaceutical's Interest & Investment Income rose 57278.79% to $570.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.8 billion, marking a year-over-year increase of 33876.94%. This contributed to the annual value of $305.6 million for FY2025, which is 1540.12% down from last year.
  • As of Q4 2025, Takeda Pharmaceutical's Interest & Investment Income stood at $570.9 million, which was up 57278.79% from $1.4 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's 5-year Interest & Investment Income high stood at $1.4 billion for Q3 2025, and its period low was -$165.6 million during Q1 2022.
  • In the last 5 years, Takeda Pharmaceutical's Interest & Investment Income had a median value of $236.2 million in 2023 and averaged $290.7 million.
  • In the last 5 years, Takeda Pharmaceutical's Interest & Investment Income surged by 114249.22% in 2021 and then tumbled by 13691.68% in 2022.
  • Over the past 5 years, Takeda Pharmaceutical's Interest & Investment Income (Quarter) stood at $36.5 million in 2021, then soared by 709.05% to $295.0 million in 2022, then crashed by 69.5% to $90.0 million in 2023, then decreased by 5.7% to $84.9 million in 2024, then surged by 572.79% to $570.9 million in 2025.
  • Its last three reported values are $570.9 million in Q4 2025, $1.4 billion for Q3 2025, and $308.9 million during Q2 2025.